Abstract
Background: The most common form of dementia is Alzheimer's disease (AD), which is characterized, in part, by the accumulation of neurofibrillary tangles (NFT), followed by synaptic and neuronal loss. NFTs are mainly composed of aggregated hyperphosphorylated Tau. It has been demonstrated that pathological concentrations of zinc induce 1] activation of a major Tau kinase – the glycogen synthase kinase-3β (GSK-3β), and 2] promote Tau aggregation and toxicity. Activity-dependent neuroprotective protein (ADNP) and its derived peptide NAP exhibit neuroprotective properties against a variety of toxic insults, including toxic zinc concentrations. ADNP deficiency results in increased content of the GSK-3β active form, Tau hyperphosphorylation and NFTlike structure formation, all of which have been prevented by NAP treatment. Our previous experiments showed that NAP enhanced Tau-microtubule association in the face of zinc toxicity. Interestingly, NAP protection against zinc toxicity was rescued by Tau overexpression in NIH-3T3 fibroblast cells, which naturally does not express high amounts of Tau.
Objectives and Methods: Pheochromocytoma cells (PC12), exposed to high concentration of zinc (400µM), were used to determine the protective effect of NAP on Tau phosphorylation and two Tau kinases (Fyn and GSK-3β). Knockdown of Tau expression in PC12 cells by RNA silencing was used to determine Tau's requirement for the NAP protective activity under zinc intoxication.
Results: NAP treatment attenuated Tau hyperphosphorylation and GSK-3β increased activity caused by zinc intoxication. Furthermore, Tau knockdown completely abolished NAP protective activity.
Conclusion: These results together with the previous findings strongly corroborated Tau's involvement in NAP/ADNP cellular activity.
Keywords: Activity-dependent neuroprotective protein (ADNP), NAP, Tau, Glycogen synthase kinase-3β (GSK-3β), Fyn, Neurofibrillary tangles (NFT), Alzheimer's disease (AD), Zinc.
Current Pharmaceutical Design
Title:NAP Protects against Tau Hyperphosphorylation Through GSK3
Volume: 24 Issue: 33
Author(s): Yanina Ivashko-Pachima and Illana Gozes*
Affiliation:
- The Lily and Avraham Gildor Chair for the Investigation of Growth Factors; The Elton Laboratory for Neuroendocrinology; Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Sagol School of Neuroscience and Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv 69978,Israel
Keywords: Activity-dependent neuroprotective protein (ADNP), NAP, Tau, Glycogen synthase kinase-3β (GSK-3β), Fyn, Neurofibrillary tangles (NFT), Alzheimer's disease (AD), Zinc.
Abstract: Background: The most common form of dementia is Alzheimer's disease (AD), which is characterized, in part, by the accumulation of neurofibrillary tangles (NFT), followed by synaptic and neuronal loss. NFTs are mainly composed of aggregated hyperphosphorylated Tau. It has been demonstrated that pathological concentrations of zinc induce 1] activation of a major Tau kinase – the glycogen synthase kinase-3β (GSK-3β), and 2] promote Tau aggregation and toxicity. Activity-dependent neuroprotective protein (ADNP) and its derived peptide NAP exhibit neuroprotective properties against a variety of toxic insults, including toxic zinc concentrations. ADNP deficiency results in increased content of the GSK-3β active form, Tau hyperphosphorylation and NFTlike structure formation, all of which have been prevented by NAP treatment. Our previous experiments showed that NAP enhanced Tau-microtubule association in the face of zinc toxicity. Interestingly, NAP protection against zinc toxicity was rescued by Tau overexpression in NIH-3T3 fibroblast cells, which naturally does not express high amounts of Tau.
Objectives and Methods: Pheochromocytoma cells (PC12), exposed to high concentration of zinc (400µM), were used to determine the protective effect of NAP on Tau phosphorylation and two Tau kinases (Fyn and GSK-3β). Knockdown of Tau expression in PC12 cells by RNA silencing was used to determine Tau's requirement for the NAP protective activity under zinc intoxication.
Results: NAP treatment attenuated Tau hyperphosphorylation and GSK-3β increased activity caused by zinc intoxication. Furthermore, Tau knockdown completely abolished NAP protective activity.
Conclusion: These results together with the previous findings strongly corroborated Tau's involvement in NAP/ADNP cellular activity.
Export Options
About this article
Cite this article as:
Ivashko-Pachima Yanina and Gozes Illana *, NAP Protects against Tau Hyperphosphorylation Through GSK3, Current Pharmaceutical Design 2018; 24 (33) . https://dx.doi.org/10.2174/1381612824666181112105954
DOI https://dx.doi.org/10.2174/1381612824666181112105954 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis, Molecular Targets, and Antitumor Activities of Substituted Tetrahydro-1- Oxopyrano[4,3-b][1]Benzopyrans and Nanogels for Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Preparation and Characterization of Methylene blue Nanoparticles for Alzheimer's Disease and Other Tauopathies
Current Drug Delivery Localisation of Endothelin-1 and its Receptors in Vascular Tissue as Seen at the Electron Microscopic Level
Current Vascular Pharmacology Older Australians: Structural barriers to learning in later life
Current Aging Science Mild Parkinsonian Signs in a Hospital-based Cohort of Mild Cognitive Impairment Types: A Cross-sectional Study
Current Alzheimer Research Biological Evaluation of Azomethine-dihydroquinazolinone Conjugates as Cancer and Cholinesterase Inhibitors
Medicinal Chemistry Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology Disturbed Sleep Patterns in Elders with Mild Cognitive Impairment: The Role of Memory Decline and ApoE ε 4 Genotype
Current Alzheimer Research Kinematic and Pressure Features of Handwriting and Drawing: Preliminary Results Between Patients with Mild Cognitive Impairment, Alzheimer Disease and Healthy Controls
Current Alzheimer Research Editorial (Thematic Issue: Mitochondrial Dysfunction and Its Relation to Translocator Protein, Oxidative Stress, mTOR Signaling, and Synaptic Protein)
Mini-Reviews in Medicinal Chemistry p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Central Nervous System Agents in Medicinal Chemistry Application of the In Combo Screening Approach For the Discovery of Non-Alkaloid Acetylcholinesterase Inhibitors from Cichorium intybus
Current Drug Discovery Technologies Subject Index To Volume 1
Recent Patents on CNS Drug Discovery (Discontinued) Patent Selections
Recent Patents on Cardiovascular Drug Discovery MicroRNA Expression Analysis of Adult-Onset Drosophila Alzheimer`s Disease Model
Current Alzheimer Research Marginal Vitamin A Deficiency Exacerbates Memory Deficits Following Aβ1-42 Injection in Rats
Current Alzheimer Research Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems
Current Neuropharmacology Obesity Promotes Oxidative Stress and Exacerbates Sepsis-induced Brain Damage
Current Neurovascular Research Frailty of Older Age: The Role of the Endocrine - Immune Interaction
Current Pharmaceutical Design Recent Trends in the Management of Alzheimer’s Disease: Current Therapeutic Options and Drug Repurposing Approaches
Current Neuropharmacology